STOCK TITAN

Incyte Genomics (INCY) Stock News, Jul-Oct 2023

INCY NASDAQ

Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.

Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.30%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
conferences earnings

FAQ

What is the current stock price of Incyte Genomics (INCY)?

Incyte Genomics (INCY) last closed at $119.09.

What is the market cap of Incyte Genomics (INCY)?

The market cap of Incyte Genomics (INCY) is approximately $24.3B.